IRIS
ALTAVILLA, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.905
NA - Nord America 9.139
AS - Asia 4.954
SA - Sud America 1.697
AF - Africa 136
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 26.850
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.996
RU - Federazione Russa 5.153
SG - Singapore 2.179
BR - Brasile 1.497
CN - Cina 1.409
IE - Irlanda 1.302
SE - Svezia 1.241
IT - Italia 835
HK - Hong Kong 539
DE - Germania 504
UA - Ucraina 482
GB - Regno Unito 325
FR - Francia 315
FI - Finlandia 265
VN - Vietnam 244
PL - Polonia 194
IN - India 139
BD - Bangladesh 67
BE - Belgio 65
TR - Turchia 60
AR - Argentina 54
CA - Canada 53
MX - Messico 50
IQ - Iraq 47
ZA - Sudafrica 41
EC - Ecuador 40
CO - Colombia 34
ES - Italia 34
ID - Indonesia 34
NL - Olanda 33
AT - Austria 32
UZ - Uzbekistan 28
MA - Marocco 24
CZ - Repubblica Ceca 23
JP - Giappone 23
VE - Venezuela 23
AE - Emirati Arabi Uniti 16
PK - Pakistan 16
IR - Iran 15
SA - Arabia Saudita 15
AZ - Azerbaigian 14
BO - Bolivia 13
AL - Albania 12
KE - Kenya 12
CL - Cile 11
LT - Lituania 11
TN - Tunisia 11
CH - Svizzera 10
CI - Costa d'Avorio 10
JO - Giordania 10
PH - Filippine 10
PY - Paraguay 10
AU - Australia 9
EG - Egitto 9
IL - Israele 9
KG - Kirghizistan 9
DO - Repubblica Dominicana 8
GR - Grecia 8
JM - Giamaica 8
KZ - Kazakistan 8
OM - Oman 8
RS - Serbia 8
NP - Nepal 7
PE - Perù 7
PS - Palestinian Territory 7
NO - Norvegia 6
UY - Uruguay 6
AM - Armenia 5
AO - Angola 5
BA - Bosnia-Erzegovina 5
BG - Bulgaria 5
GE - Georgia 5
LB - Libano 5
NI - Nicaragua 5
PA - Panama 5
RO - Romania 5
BY - Bielorussia 4
DZ - Algeria 4
ET - Etiopia 4
HN - Honduras 4
KW - Kuwait 4
LV - Lettonia 4
SK - Slovacchia (Repubblica Slovacca) 4
SN - Senegal 4
SV - El Salvador 4
TH - Thailandia 4
CR - Costa Rica 3
DK - Danimarca 3
HR - Croazia 3
HU - Ungheria 3
KR - Corea 3
MY - Malesia 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
XK - ???statistics.table.value.countryCode.XK??? 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BW - Botswana 2
EE - Estonia 2
EU - Europa 2
GA - Gabon 2
Totale 26.819
Salva come PNG Salva come JPEG
Città #
Moscow 1.476
Dublin 1.302
Ashburn 1.262
Singapore 1.170
Chandler 990
Jacksonville 942
Dallas 914
Nyköping 691
Hong Kong 534
Beijing 486
San Jose 372
The Dalles 294
Dearborn 251
Ann Arbor 244
Los Angeles 243
Princeton 218
Cambridge 199
Medford 199
Warsaw 187
Lauterbourg 183
New York 162
Messina 160
Des Moines 152
Boardman 130
Munich 121
São Paulo 116
Lancaster 110
Buffalo 88
Tianjin 82
Jinan 78
Ho Chi Minh City 75
Woodbridge 67
Brussels 62
Shenyang 52
Orem 51
Redondo Beach 51
Rio de Janeiro 51
Guangzhou 50
Hanoi 50
Turku 50
Wilmington 48
San Mateo 45
Santa Clara 44
Frankfurt am Main 42
Houston 40
Nanjing 36
Belo Horizonte 35
Council Bluffs 30
Hyderabad 29
Rome 29
Catania 28
Hebei 27
Vienna 27
Brasília 26
Brooklyn 26
Chicago 26
Pune 26
Tashkent 26
Zhengzhou 26
Atlanta 25
Milan 25
Montreal 24
San Francisco 24
Seattle 24
Jakarta 23
Tokyo 23
London 22
Baghdad 21
Washington 21
Curitiba 20
Denver 20
Haikou 20
Helsinki 20
Nanchang 20
Porto Alegre 20
Chennai 19
Düsseldorf 19
Mumbai 19
Nuremberg 19
Stockholm 19
Istanbul 18
Johannesburg 18
Shanghai 18
Dong Ket 17
Ningbo 17
Norwalk 17
Salvador 17
Boston 16
Quito 16
Ankara 15
Bremen 15
Campinas 15
Phoenix 15
Ribeirão Preto 15
Scarsdale 15
Shenzhen 15
Brno 14
Hangzhou 14
Taizhou 14
Amsterdam 13
Totale 15.292
Salva come PNG Salva come JPEG
Nome #
PARAGANGLIOMA MALIGNO DEL CORPO CAROTIDEO.Rilievi Clinici, Morfologici, Istochimici E Ultrastrutturali Su Un Caso. 426
Amplification and overexpression of the PSMB5 gene contributes to bortezomib resistance in retreatment of patients with multiple myeloma. 233
Annual increase in the frequency of papillary thyroid carcinoma as diagnosed by fine-needle aspiration at a cytology unit in Sicily. 228
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy 226
Analysis of multilayer strain and myocardial work in patients undergoing chemotherapy treatment: a 12 months follow-up 224
Mechanical dispersion and cardiotoxicity in patients who underwent chemotherapy for breast cancer: an echocardiographic study 222
zd1839"iressa" in heavily pretreated patients with advaned/metastatic non-small cell lung cancer(NSCLC):assessment of tolerability and the clinical benefit 221
Bone and lymph node metastases from occult mammary carcinoma: a case report of carcinoma of unknown primary (CUP) Syndrome 218
A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations 217
Analisi dello stato di metilazione del promoter di O6-methylguanine DNA methyltransferase (MGMT) e TMS1/ASC nei gliomi cerebrali diffusi di basso grado: possibili implicazioni cliniche e prognostiche. 214
Su di un caso di pseudomyxoma peritonei con diffusione spontanea alla pleura. 211
Apelin beyond kidney failure and hyponatremia: a useful biomarker for cancer disease progression evaluation 208
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC) 204
Epirubucin (EPI) and Paclitaxel (TAX) in advanced breast cancer.a phase II studyi 200
Myocardial damage pattern in women with breast cancer who underwent chemotherapy: strain polar maps analysis 199
Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy 197
Liver dysfunction in hcv infected patients with CD20-Positive B-Cell Lymphoma undergoing rituximab combination chemotherapy 191
EML4-ALK fusion gene in lung adenocarcinoma: A retrospective analysis of the outcome of cisplatin plus pemetrexed treated patients. 190
[Serum levels of copper and zinc in patients with lung cancer] 189
Should the Use of Surveillance Imaging in Diffuse Large B-Cell Lymphoma Be Discontinued? 186
A study of endometrial adenocarcinoma treated with tamoxifen by scanning and transmission electron microscopy. 186
Liquid biopsy for lung cancer early detection 185
An acute-leukaemia-like picture due to breast carcinoma cells. 184
Alectinib: A selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer 184
Applications of genomics in NSCLC 183
Increased annual frequency of Hashimoto's thyroiditis between years 1988 and 2007 at a cytological unit of Sicily. 183
Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer 183
Left atrial function in patients undergoing chemotherapy: additional value of 2D longitudinal strain 182
Gemcitabine (GEM) and cisplatin (CIS) in advanced/metastatic transitional cell carcinoma (TCC) of bladder:phase II study 181
A PHASE II STUDY (21 DAY REGIMEN) OF GEMCITABINE AND CISPLATIN IN TRANSITIONAL CELL CARCINOMA OF BLADDER 181
[(186)Re]HEDP in the palliation of painful bone metastases from cancers otherthan prostate and breast. 179
Evaluation of quality of life of patients submitted to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis of gastrointestinal and ovarian origin and identification of factors influencing outcome. 179
Cancer screening in HIV-infected patients: early diagnosis in a high-risk population 179
Endocrine toxicity of immune checkpoint inhibitors (anti-PD-1/PD-L1) in advanced cancer 179
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 178
A randomized factorial trial of sequential doxrubicina and CMF vs CMF and chemoterapy alone vs chemoterapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer 178
ANALYSES AND DETERMINATION OF LONIDAMINE RELEASE FROM PHARMACEUTICAL FORMULATION. 175
Amplification and overexpression of the PSMB5 gene contribute to Bortezomib resistance in re-treatment of patients with Multiple Myeloma 172
Early assessment of chemotherapy-related cardiovascular toxicity in patients with breast cancer 172
A novel HPLC method for the determination of mitoxantrone in pharmaceutical formulations. 171
Bleomycin, epirubicin, carboplatin (BECA) in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck 170
A PHASE III RANDOMIZED TRIAL COMPARING THREE PLATINUM-BASED DOUBLETS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): IMPACT OF PS=2 VS 0 OR 1 AND AGE ³70 VS <70 ON CHEMOTHERAPY OUTCOME 169
The treatment of peritoneal carcinomatosis in elderly patients. 168
Espressione differenziale di un panel di miRNA in tumori cerebrali astrogliali con diverso grado di malignità. 167
Analytical profile and release of lonidamine from pharmaceutical formulation 165
Gemcitabine (GEM) and cisplatin (Cis) in advanced/metastatic transitional cell carcinoma (TCC) of bladder: Phase II study 165
Razionale e tecniche della chirurgia citoriduttiva e della chemioipertermia peritoneale. 165
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: a phase II study. J Chemother. 1999 Feb;11(1):74-7. PMID: 10078785 [PubMed - indexed for MEDLINE] 164
A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin 163
Myelodysplastic syndrome appearing during imatinib mesylate therapy in a patient with GIST 163
Antiblastic treatment of advanced cervical carcinoma and its recurrences: assessment of four different polychemotherapies used for a decade. 163
HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy. 163
Thyroid hormone autoantibodies: Are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? 162
Unusual relapse of hepatocellular carcinoma 161
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 160
90Y-IBRITUMOMAB TIUXETAN CONSOLIDATION AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IMPROVES SURVIVAL OF INTERMEDIATE/HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS NOT RESPONDING ADEQUATELY TO FIRST 160
Psycho-Neuro-Endocrine-Immune System (PNEI) Involvement as Prognostic Marker in Breast Cancer Patients at 10 Years of Follow Up 159
ZD 1839 IRESSA IN HEAVILY PRETREATED PATIENTS WITH ADVANCED/METASTATIC NON SMALL CELL LUNG CANCER:ASSESSMENT OF TOLERABILITY AND CLINICAL BENEFIT 156
Etoposide, l-leucovorin and fluorouracil (ELF) regimen in metastatic gastric cancer: A phase II study 155
Author Correction to: Prevalence of Use and Cost of Biological Drugs for Cancer Treatment: A 5-Year Picture from Southern Italy 155
Surgical treatment for congestive heart failure with autologous adult stem cell transplantation 152
Targeted drugs in small-cell lung cancer 152
Association between XPD 312 single nucleotide polymorphism (SNP) and clinical outcome in stage IIIA-B non-small-cell lung cancer (NSCLC) patients (P) < 59 years (Y) treated with chemotherapy followed by surgery 151
La farmacogenomica nei tumori del polmone 150
Risk of occult hepatitis B virus infection reactivation in patients with solid tumours undergoing chemotherapy 150
Sternal metastasis as initial presentation of a unknown rectal cancer 149
Peritoneal carcinomatosis of colorectal origin. 149
Trattamento palliativo dei tumori del retto-sigma mediante elettrocoagulazione endoscopica.” 149
First Line Chemotherapy with Oral Vinorelbine (oV) in Elderly Hormone-Refractory Prostate Cancer (HRPC) Patients (pts 148
Severe pulmonary complications after bortezomib treatment for multiple myeloma: An unrecognized pulmonary vasculitis? 146
Clodronate and radiotherapy for the treatment of osteolysis caused by metastasis of breast carcinoma and non-small cell lung carcinoma. A retrospective study 145
Thyroid function, autoimmunity and nodules in hematological malignancies 144
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases 141
Gemcitabine combined with Oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma 141
Extramedullary plasmacytoma presented as a non-functional invasive pituitary macro-adenoma. 140
Salvage therapy for primary central nervous system lymphoma with Y-90-Ibritumomab and Temozolomide 140
Transpersonal Therapy Combined with Best Supportive Care In Hospice Improve Patient’s Quality of Life and Quality Of Death 140
Retrospective analiysis of P-STAT6 expression as predictive marker in primary nervous system lymphoma patients assigned to high-dose methotrexate 139
Treatment of advanced and/or metastatic epidermoid carcinoma of the head and neck: an effective combination chemotherapy with bleomycin, methotrexate and ftorafur. 139
A PHASE II STUDY (21 day regimen) OF GEMCITABINE (Gem) AND CISPLATIN ( Cis) IN ADVANCED/METASTATIC TRANSITIONAL CELL CARCINOMA (TTC) OF BLADDER 138
Studio anatomo-clinico di due casi di sarcoma sinoviale monofasico del ginocchio 138
SUBCUTANEOUS LOW-DOSE ALEMTUZUMAB AS FIRST LINE THERAPY FOR ELDERLY CLL PATIENTS WITH DELETION OF 17p 137
DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients 137
Use of bisphosphonates in oncology 135
Beyond global longitudinal strain: early impairment of apical function after antracyclines therapy 134
Temozolomide-induced shrinkage of a pituitary carcinoma. 134
Relapsed or refractory extranodal DLBCL treated with lenalidomide: A single center study 134
How cells respond to interferons. 132
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study. 132
Behavior of serum sialic acid levels at various stages of neoplastic disease 131
MYELODYSPLASTIC SYNDROMES DEVELOPING DURING IMATINIB THERAPY FOR GIST 131
Serum levels of copper and zinc in patients with lung cancer 130
ERLOTINIB IN A PATIENT WITH ACUTE MYELOGENOUS LEUKEMIA AND CONCOMITANT NON-SMALL-CELL LUNG CANCER 129
Imatinib-induced apoptosis in the eosinophils of patients with a hypereosinophilic syndrome: A surrogate marker of response? 129
DASATINIB INDUCES A RESPONSE IN CHRONIC LYMPHOCYTIC LEUKEMIA 127
Efficacy and toxicity of weekly Docetaxel as second/third line chemotherapy for advanced Non Small Cell lung cancer (NSCLC) 126
Gemcitabine as single agent in the treatment of elderly patients with advanced non small cell lung cancer 125
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). 124
VP16, epirubicin and procarbazine in the treatment of advanced non-small-cell lung cancer. 123
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study 121
Totale 16.763
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.007
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021354 0 0 0 0 0 0 0 0 0 169 118 67
2021/20221.548 10 224 45 40 58 20 84 60 31 244 269 463
2022/20233.895 309 370 174 284 303 396 57 235 1.601 22 95 49
2023/2024988 73 128 66 114 73 258 23 45 3 79 26 100
2024/20254.298 57 38 74 252 221 134 75 1.015 1.146 250 337 699
2025/202611.495 617 662 1.003 691 969 2.672 1.495 1.488 1.493 405 0 0
Totale 27.136